HEALTH● LOW1h ago · Oct 22, 2026, 2:33 PM
AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa
Seeking Alpha Tech · global
AbbVie has reported positive late-stage clinical trial results for its drug lutikizumab in treating hidradenitis suppurativa. This is significant for potential new treatment options for the condition and for the company's pharmaceutical pipeline.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH14m agoFrance records first human death linked to Shamonda virusVanguard NigeriaHEALTH17m agoEbola: Africa CDC says Nigerian patient was born in UgandaVanguard NigeriaHEALTH20m ago‘Flesh-eating’ screwworm confirmed in US wildlife as officials scramble to contain spreadThe Independent WorldHEALTH22m agoEbola: Enugu intensifies surveillance across 17 LGAsVanguard Nigeria